Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IDEXX Laboratories Inc Lowers FY 2013 Guidance


Tuesday, 23 Apr 2013 07:00am EDT 

IDEXX Laboratories Inc announced that for fiscal 2013, it expects revenues to be $1.38 billion to $1.39 billion, organic growth is estimated to be in the range of 7.5% to 8%, as compared with previous guidance of 8% to 9%, reflective of organic growth in the first quarter and an anticipated reduction in capital equipment sales in ensuing quarters from previous guidance. The decrease in expected reported revenue is the result of unfavorable changes in foreign currency exchange rates, reflecting a strengthening of the U.S. dollar relative to other currencies since the date of previous guidance, as well as the reduction in outlook for 2013 organic growth. EPS are expected to be $3.40 to $3.46 on a GAAP and non-GAAP basis. This compares to previous guidance which reflected EPS of $3.47 to $3.57 on a GAAP basis and $3.42 to $3.52 on a non-GAAP basis. EPS on a non-GAAP basis are adjusted to exclude the favorable impact of the retroactive extension of the 2012 federal R&D tax credit and the unfavorable impact of the third-party service provider's bankruptcy. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.401 billion and EPS of $3.54 for fiscal 2013. 

Company Quote

148.24
0.26 +0.18%
19 Dec 2014